PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
| Metabolism | Phentermine is partially metabolized by CYP3A4 to N-hydroxyphentermine; topiramate is not extensively metabolized (~70% excreted unchanged), with minor metabolism via hydroxylation, hydrolysis, and glucuronidation. |
| Excretion | Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined. |
| Half-life | Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing. |
| Protein binding | Phentermine: 50-60% bound (albumin). Topiramate: 15-41% bound (albumin). |
| Volume of Distribution | Phentermine: 3-4 L/kg (extensive tissue distribution including brain). Topiramate: 0.6-0.8 L/kg (predominantly extracellular fluid). |
| Bioavailability | Phentermine: 100% oral (immediate release). Topiramate: 80-100% oral (food not clinically significant). |
| Onset of Action | Oral: Weeks to months for weight loss; peak effect at 6-12 weeks. Immediate appetite suppression may occur within days but objective weight loss requires sustained therapy. |
| Duration of Action | Phentermine: Supports once-daily dosing (24-hour effect on satiety). Topiramate: Sustained release due to long half-life; clinical weight loss effect persists with continuous dosing; note: 24-hour duration for weight loss. |
| Molecular Weight | 100.16 |
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl ≥50 mL/min: No adjustment. CrCl 30-49 mL/min: Limit to 7.5 mg/46 mg once daily. CrCl <30 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Limit to 7.5 mg/46 mg once daily. Child-Pugh C: Contraindicated. |
| Pediatric use | Not approved for use in pediatric patients aged <18 years. No established dosing guidelines. |
| Geriatric use | No specific dose adjustment. However, use with caution due to age-related renal impairment; consider renal function and start at lowest dose. Not recommended in patients >65 years due to limited data. |
| 1st trimester | Topiramate is associated with increased risk of oral clefts if used during first trimester. Phentermine has limited data but is generally avoided due to theoretical risks. Use only if benefit outweighs risk. |
| 2nd trimester | Topiramate may cause fetal growth restriction and oligohydramnios. Phentermine should be avoided due to potential maternal and fetal effects. |
| 3rd trimester | Topiramate may cause neonatal metabolic acidosis and withdrawal if used near term. Phentermine may cause neonatal withdrawal or toxicity. Avoid use. |
Clinical note
Can decrease efficacy of oral contraceptives and other drugs by inducing CYP450 enzymes Can cause metabolic acidosis and angle-closure glaucoma.
| Placental transfer | Topiramate readily crosses the placenta achieving fetal plasma concentrations similar to maternal. Phentermine likely crosses placenta based on molecular weight. |
| Breastfeeding | Topiramate is excreted in breast milk at low concentrations (10-20% of maternal serum levels). Phentermine is excreted in breast milk; potential for infant stimulation and sleep disturbance. Use with caution, monitor infant for adverse effects. |
■ FDA Black Box Warning
None.
| Common Effects | migraine prevention |
| Serious Effects |
Hypersensitivity to sympathomimetic amines or topiramateConcomitant use with MAOIs or within 14 days of discontinuationHyperthyroidismGlaucomaAgitated statesHistory of drug abusePregnancy (for topiramate due to teratogenicity)
| Precautions | Increased heart rate, suicidal behavior/ideation, acute myopia/secondary angle closure glaucoma, mood disorders, cognitive impairment, metabolic acidosis, seizures (with topiramate withdrawal), pancreatitis, kidney stones, hypohidrosis/hyperthermia, fetal toxicity (orofacial clefts). |
| Food/Dietary | Grapefruit or grapefruit juice may increase phentermine levels; avoid concurrent consumption. High-fat meals may increase absorption; take consistently with or without food. Avoid alcohol. Maintain adequate hydration to prevent kidney stones (topiramate increases risk of nephrolithiasis). |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data; potential for infant effects. |
| Teratogenic Risk | Phentermine/topiramate is pregnancy category X. First trimester: Increased risk of oral clefts (topiramate). Second/third trimester: Potential for fetal growth restriction, oligohydramnios, and metabolic acidosis. Topiramate may cause neural tube defects if folate antagonist effects are not mitigated. |
| Fetal Monitoring | Monitor fetal growth via ultrasound and amniotic fluid index. Assess for signs of oligohydramnios. In neonates, monitor for hypoglycemia, hyperbilirubinemia, and metabolic acidosis. Maternal monitoring includes renal function, electrolytes, and metabolic acidosis risk. |
| Fertility Effects | Topiramate may cause menstrual irregularities and anovulation. Phentermine may reduce fertility due to weight loss. Reversible upon discontinuation. |
| Clinical Pearls | Phentermine/topiramate ER (Qsymia) is used for chronic weight management in adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidity. Topiramate component may cause metabolic acidosis; monitor serum bicarbonate periodically. Risk of increased heart rate; contraindicated in recent/unstable cardiac disease. Abrupt discontinuation may cause seizures; taper over 1 week. Fetal risk: topiramate is teratogenic; rule out pregnancy before initiation and monthly thereafter. CYP450 interactions: topiramate is a weak CYP3A4 inducer and CYP2C19 inhibitor. |
| Patient Advice | Take this medication exactly as prescribed, once daily in the morning; avoid taking in the evening to prevent insomnia. · You may experience dry mouth, constipation, or tingling in hands/feet; these are common side effects. · Do not stop this medication suddenly; your dose must be tapered down to prevent seizures. · This drug can cause birth defects; use effective contraception and inform your doctor if you become pregnant or plan to become pregnant. · Avoid alcohol while taking this medication as it may increase dizziness or drowsiness. |